Never before, scientists say, the universal community of researchers have put a halt to all other ongoing research and have urgently focused towards swiftly evolving health emergency. In the past few months, scientists have been repurposing their research efforts towards contributing to the global effort in response to COVID-19 pandemic.
For the purpose of mitigating COVID-19, scientists are racing up the experimental studies to find a suitable and promising drug class that might be effective in tackling the highly contagious virus. Specifically, researchers are developing rapid, laboratory diagnostic kits that involve the use of mission-critical oligo chemistries.
Apart from the diagnostic applications, a major proportion
of the demand for oligonucleotides comes from different research projects. Over
the past few years, multiple initiatives have been undertaken to develop oligonucleotide-based
interventions in order to treat a myriad of chronic clinical conditions.
Experts believe that oligonucleotides are likely to evolve into one of the key
therapeutic classes of the future, given their high specificity and favorable
biological tolerance profiles.
Significant advances have been made in enhancing the
drug-like properties of such molecules, including tissue targeting capability,
cellular internalization feature, endosomal escape capability, target binding
specificity, and resistance to nucleases.
In this context, bioconjugation chemistry has played an
important role in oligo-based therapy development, offering the means to
combine the target specificity of these molecules with the therapeutic benefits
of other potent drug substances. In fact, many are led to believe that
oligonucleotide drug conjugates market is poised to witness significant growth
Further, several new companies have come up with innovative
technologies to develop oligonucleotide-based therapeutics.
In recent times, such innovator companies have started investing heavily in R&D
and have resulted in the establishment of a rich pipeline of oligonucleotide-based
drug products. In order to meet the growing demand, a number of small- to
mid-sized companies have begun outsourcing their manufacturing operations to
contract / custom service providers.
In fact, several big pharma companies,
despite having proprietary manufacturing capabilities, are known to outsource
more than half of their clinical stage oligonucleotide manufacturing
operations. In the foreseen future, we anticipate the demand and opportunities
for contract manufacturing organizations (CMO) in this domain to rise.
Service Providers Offering Oligonucleotide Manufacturing
Currently, close to 80 service providers claim to offer oligonucleotide-related synthesis, modification and purification services for various research, diagnostic and therapeutic applications, across the globe.
To know about the companies that are engaged in the manufacturing of oligonucleotides, check out our report – Oligonucleotide Synthesis.
Capacity with the Companies (in kgs) – Enough to
Meet the Demand?
The current, annual capacity is primarily driven by players operating at the commercial scale, which represent 96% of the total manufacturing capacity. In addition, around 82% of the capacity belongs to large-scale manufacturers of oligonucleotides. Further, around 92% of this capacity is estimated to be installed in developed regions, such as North America and Europe.
Likely Growth of the Oligonucleotide Manufacturing Market
North America (primarily the US) is the current market leader in the oligonucleotide manufacturing market; this developed market is anticipated to grow at an annualized rate of 8.7%, till 2030. Due to relatively low labor costs and less stringent regulatory guidelines, the market in Asia-Pacific is expected to grow at a significantly faster rate in the coming decade.
To get a detailed information on the key players, recent developments, capacity available and manufacturing demand for oligonucleotides and the likely market evolution.